Infinitt Healthcare Co Ltd

Infinitt Healthcare maintains a strong liquidity position with a current ratio of 5.55, indicating a robust ability to meet short-term obligations. The company's liquidity FPT (free cash flow to total debt) is favorable, supported by a free cash flow of 26,191,675,800 KRW and a low long-term debt of 2,522,821,950 KRW. However, the risk assessment notes that net cash is negative after subtracting total debt, signaling a potential liquidity risk. Profitability metrics show a return on equity (ROE) of 13.77% and a return on assets (ROA) of 10.61%, both exceeding the industry median for Advanced Medical Equipment & Technology. The company's gross margin of 61.5% (62,962,276,700 KRW gross profit on 102,391,971,530 KRW revenue) is also above the industry median, indicating efficient cost management and pricing power. Geographically, Infinitt Healthcare's revenue is concentrated in the domestic market, with limited exposure to overseas markets such as America and Europe. The company does not disclose segment-specific revenue figures, but its product portfolio spans radiology, dental, and cardiology PACS, suggesting a diversified product offering within the healthcare imaging space. The company's growth trajectory is supported by a strong operating cash flow of 13,691,104,680 KRW and a free cash flow of 26,191,675,800 KRW. While no specific revenue growth rate is provided, the company's capital expenditure of -433,840,480 KRW suggests a focus on cost optimization rather than aggressive expansion. The outlook for the current fiscal year is stable, with no significant changes in revenue or profitability expected. Risk factors include a medium liquidity risk due to the negative net cash position after debt, and a low dilution risk as the company has not issued new shares recently. The risk assessment also notes a low dilution potential, with no significant dilution sources identified in the latest filings or transcripts. Recent events include the sale of its 70% stake in TI Medical Systems Co., Ltd. in 2013, which focused on electrical medicine machines. No recent filings or transcripts have been disclosed that would indicate significant changes in the company's strategic direction or financial performance.